GlassScriptPhysician profile
Jack L Armstrong
NPI 1972569911
$84,608.73
in general payments reported to CMS, 2019-2025
47 companies · $3,351 in 2025
The $3,351 reported for 2025 was more than what 78% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,010 · 2020: $1,979 · 2021: $3,101 · 2022: $3,461 · 2023: $10K · 2024: $61K · 2025: $3,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $60K · Food and Beverage: $13K · Travel and Lodging: $1,478 · Education: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $59,850.00 |
| Food and Beverage | $12,501.48 |
| Travel and Lodging | $1,478.49 |
| Education | $227.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $67,662.23 | 2019-2024 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $2,977.95 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $2,377.05 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,393.28 | 2019-2024 | |
| Pfizer INC. | $1,356.00 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,113.72 | 2020-2025 | Cuvitru, Hyqvia, Eohilia |
| Genentech USA, INC. | $886.31 | 2019-2025 | Xolair |
| Optinose US, INC. | $755.94 | 2019-2025 | |
| Grifols USA, LLC | $717.01 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Abbvie INC. | $685.11 | 2022-2025 | Ubrelvy, Rinvoq, Qulipta |
| Amgen INC. | $669.28 | 2021-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $560.81 | 2019-2025 | |
| Csl Behring | $460.09 | 2019-2025 | Hizentra, Andembry, Haegarda |
| Covis Pharma Gmbh | $324.97 | 2021-2022 | |
| Biocryst US Sales Co., LLC | $277.05 | 2021-2025 | Orladeyo |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Armstrong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.